Inhibition of the renin-angiotensin system and cardiorenal protection

Focus on losartan and angiotensin receptor blockade

Aneliya Parvanova, Carlos Chiurchiu, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Angiotensin II plays a central role in the pathogenesis and progression of proteinuric nephropathies and related cardiovascular complications. Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs. Losartan has demonstrated renoprotective effects in animals and humans with diabetic and non-diabetic renal diseases similar to those of angiotensin-converting enzyme inhibitors, with a lower incidence of dry cough and angioneurotic oedema. A reduced incidence of cerebrovascular events and diabetes has been reported in hypertensive patients with left ventricular hypertrophy on losartan therapy compared with patients treated with atenolol. Whether ARBs have superior cardioprotective effects, compared with other blood pressure medications, is still unknown. Combined angiotensin-converting enzyme inhibitor and ARB therapy improves renal outcomes in non-diabetic nephropathies more than single drug renin-angiotensin system inhibition. Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown.

Original languageEnglish
Pages (from-to)1931-1942
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number11
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Angiotensin Receptors
Losartan
Renin-Angiotensin System
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Kidney
Angioedema
Atenolol
Incidence
Diabetic Nephropathies
Left Ventricular Hypertrophy
Cough
Angiotensin II
Blood Pressure
Therapeutics
Pharmaceutical Preparations

Keywords

  • Angiotensin II
  • AT1-receptor blockers
  • Diabetic and non-diabetic nephropathies
  • Losartan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Inhibition of the renin-angiotensin system and cardiorenal protection : Focus on losartan and angiotensin receptor blockade. / Parvanova, Aneliya; Chiurchiu, Carlos; Ruggenenti, Piero; Remuzzi, Giuseppe.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 11, 09.2005, p. 1931-1942.

Research output: Contribution to journalArticle

@article{4a3cbdcabc5549ccb6a213ec0f1e9fbb,
title = "Inhibition of the renin-angiotensin system and cardiorenal protection: Focus on losartan and angiotensin receptor blockade",
abstract = "Angiotensin II plays a central role in the pathogenesis and progression of proteinuric nephropathies and related cardiovascular complications. Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs. Losartan has demonstrated renoprotective effects in animals and humans with diabetic and non-diabetic renal diseases similar to those of angiotensin-converting enzyme inhibitors, with a lower incidence of dry cough and angioneurotic oedema. A reduced incidence of cerebrovascular events and diabetes has been reported in hypertensive patients with left ventricular hypertrophy on losartan therapy compared with patients treated with atenolol. Whether ARBs have superior cardioprotective effects, compared with other blood pressure medications, is still unknown. Combined angiotensin-converting enzyme inhibitor and ARB therapy improves renal outcomes in non-diabetic nephropathies more than single drug renin-angiotensin system inhibition. Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown.",
keywords = "Angiotensin II, AT1-receptor blockers, Diabetic and non-diabetic nephropathies, Losartan",
author = "Aneliya Parvanova and Carlos Chiurchiu and Piero Ruggenenti and Giuseppe Remuzzi",
year = "2005",
month = "9",
doi = "10.1517/14656566.6.11.1931",
language = "English",
volume = "6",
pages = "1931--1942",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Inhibition of the renin-angiotensin system and cardiorenal protection

T2 - Focus on losartan and angiotensin receptor blockade

AU - Parvanova, Aneliya

AU - Chiurchiu, Carlos

AU - Ruggenenti, Piero

AU - Remuzzi, Giuseppe

PY - 2005/9

Y1 - 2005/9

N2 - Angiotensin II plays a central role in the pathogenesis and progression of proteinuric nephropathies and related cardiovascular complications. Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs. Losartan has demonstrated renoprotective effects in animals and humans with diabetic and non-diabetic renal diseases similar to those of angiotensin-converting enzyme inhibitors, with a lower incidence of dry cough and angioneurotic oedema. A reduced incidence of cerebrovascular events and diabetes has been reported in hypertensive patients with left ventricular hypertrophy on losartan therapy compared with patients treated with atenolol. Whether ARBs have superior cardioprotective effects, compared with other blood pressure medications, is still unknown. Combined angiotensin-converting enzyme inhibitor and ARB therapy improves renal outcomes in non-diabetic nephropathies more than single drug renin-angiotensin system inhibition. Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown.

AB - Angiotensin II plays a central role in the pathogenesis and progression of proteinuric nephropathies and related cardiovascular complications. Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs. Losartan has demonstrated renoprotective effects in animals and humans with diabetic and non-diabetic renal diseases similar to those of angiotensin-converting enzyme inhibitors, with a lower incidence of dry cough and angioneurotic oedema. A reduced incidence of cerebrovascular events and diabetes has been reported in hypertensive patients with left ventricular hypertrophy on losartan therapy compared with patients treated with atenolol. Whether ARBs have superior cardioprotective effects, compared with other blood pressure medications, is still unknown. Combined angiotensin-converting enzyme inhibitor and ARB therapy improves renal outcomes in non-diabetic nephropathies more than single drug renin-angiotensin system inhibition. Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown.

KW - Angiotensin II

KW - AT1-receptor blockers

KW - Diabetic and non-diabetic nephropathies

KW - Losartan

UR - http://www.scopus.com/inward/record.url?scp=25444450810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444450810&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.11.1931

DO - 10.1517/14656566.6.11.1931

M3 - Article

VL - 6

SP - 1931

EP - 1942

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -